Wound management needs to change.

Wound management has been stagnant for decades. After 6 months of current best practice, healing is seen in less than 50% of the world’s intractable wounds (Maida et al, 2021). Chronic wounds are major drivers of serious global healthcare trends, including opioid crisis and proliferation of antibiotic “superbugs”

The WHO states chronic wounds are a “Major Global Public Health Crisis”, affecting up to 6% of the population.

Despite 3000 types of dressings, there is no product that consistently heals chronic wounds like venous leg ulcers, diabetic wounds and pressure ulcers (Dhivya et al, 2015).

Patient outcomes with current best practice:

Our unique approach creates invaluable results.

The endocannabinoid system is implicated in nearly every single body system, including the biggest, heaviest, and most ubiquitous – the Integumentary System. Chronic wounds are pathologic states marked by dysregulation of the integumentary endocannabinoid system.

Kensana Health’s proprietary oral and topical treatments involving the enhancement of endocannabinoid functionality work in ways previously not seen in wound management:

What was ‘Non-healing’ is now ‘Complete wound closure’.

A series of experiments were conducted with a variety of previously non-healing patients who had been treated (unsuccessfully) with the current gold standard for 6 months or more prior to their Kensana Health treatment.

Our proprietary treatments achieved over 80% complete wound closure. For instance, in patients with previously non-healing venous leg ulcers this result was achieved in a median 34 days (Maida et al, 2021). Additionally, complete healing was shown in our first target, calciphylaxis, a rare disease with up to 80% mortality within 12 months.

The exceptional results of Kensana Health’s First-In-Human trials provide unique insights into impending results of regulatory-controlled trials.

The COVID-19 pandemic highlights the problems with an unreliable supply chain. Kensana Health, from its beginnings, was built with a vertically-integrated model.

Internally controlling all aspects of the supply chain, from harvesting GMP-grade APIs from plants, produced in a cutting-edge environmentally-controlled cultivation system, through to our extraction and FDA-compliant GMP pharmaceutical manufacturing facilities.

Our shared vision and strategic partnership with MB-Holding enables us to complete our vertical integration.

Assoc. Professor Vincent Maida MD MSc BSc CCFP(PC) FCFP ABHPM FRCP(cand)

Professor Marco Romanelli MD PhD

Deep and Broad Protection Treating the Integumentary System

Kensana Health has a strong leadership position being first in the field with a broad portfolio of patent applications and trade secrets involving cannabinoid therapies in wound management. Following the acquisition of VinSan Therapeutics in 2021, Kensana Health’s IP has the earliest priority date, with a broad scope of IP, covering both wound and integument.

Kensana Health is set to create a paradigm shift in wound management.

References

Dhivya, S., Padma, V.V. and Santhini, E., 2015. Wound dressings–a review. BioMedicine, 5(4), pp.1-5.

Maida, V., Shi, R.B., Fazzari, F.G.T. and Zomparelli, L.M., 2021. Topical Cannabis‐Based Medicines–A Novel Adjuvant Treatment for Venous Leg Ulcers: An Open‐Label Trial. Experimental Dermatology.